One thing we could say about the analysts on Sensus Healthcare, Inc. (NASDAQ:SRTS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

After this downgrade, Sensus Healthcare's three analysts are now forecasting revenues of US$40m in 2026. This would be a meaningful 12% improvement in sales compared to the last 12 months. Losses are predicted to fall substantially, shrinking 67% to US$0.06 per share. Prior to this update, the analysts had been forecasting revenues of US$45m and earnings per share (EPS) of US$0.14 in 2026. There looks to have been a major change in sentiment regarding Sensus Healthcare's prospects, with a substantial drop in revenues and the analysts now forecasting a loss instead of a profit.

Check out our latest analysis for Sensus Healthcare

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that Sensus Healthcare's revenue growth is expected to slow, with the forecast 9.4% annualised growth rate until the end of 2026 being well below the historical 16% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 8.4% annually. Factoring in the forecast slowdown in growth, it looks like Sensus Healthcare is forecast to grow at about the same rate as the wider industry.

The biggest low-light for us was that the forecasts for Sensus Healthcare dropped from profits to a loss next year. Lamentably, they also downgraded their sales forecasts, but the business is still expected to grow at roughly the same rate as the market itself. After a cut like that, investors could be forgiven for thinking analysts are a lot more bearish on Sensus Healthcare, and a few readers might choose to steer clear of the stock.

Still, the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Sensus Healthcare going out to 2027, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.